Acelyrin, Inc.

Acelyrin ended Q3 2024 with $562.4 million in cash. R&D expense was $31.6 million versus $74.6 million in the same period of 2023, and G&A expense was $12.3 million versus $19.9 million a year ago. The company said it transformed its manufacturing commitments for izokibep into a net expense of $7.2 million, consisting of a $42.9 million payment and a $35.7 million credit voucher. It updated year-end cash guidance to $435 million to $450 million from $420 million to $450 million previously, including an expected $31 million Q4 license option payment for full global rights to lonigutamab. Management said current cash provides runway to at least mid-2027, excluding any new investments in izokibep. No revenue or EPS figures were reported in the call text provided.

Mina Kim framed the quarter as transformative, saying the company has refocused its pipeline and corporate strategy around lonigutamab in TED. She emphasized FDA alignment, the strength of the dose-ranging data so far, and the company’s confidence in launching Phase 3 in Q1 2025. Her tone was constructive but measured, repeatedly stressing disciplined, capital-conscious execution and that the uveitis decision will be made only after the December data readout.

Gil Labrucherie highlighted the balance sheet and cost reset, pointing to $562.4 million in cash at quarter-end and a runway to at least mid-2027. He said R&D declined to $31.6 million from $74.6 million and G&A fell to $12.3 million from $19.9 million, largely due to lower clinical activity and stock-based compensation. He also detailed the izokibep manufacturing resolution: a $42.9 million payment offset by a $35.7 million credit voucher, which he said should help offset future manufacturing cash outflows in 2025 and early 2026. He noted the company added an ATM facility for future flexibility, but emphasized disciplined capital allocation.

Questions centered on what data FDA saw in the end-of-Phase 2 lonigutamab meeting, whether Cohort 4 would shape the pivotal dose, and how the company thinks about hearing-risk mitigation versus Tepezza. Management said the FDA meeting reflected the totality of the dose-ranging data available, with Cohort 4 mainly serving as a loading-dose/PK confirmation cohort and not a broad new dosing pillar. On uveitis, analysts pressed on what would count as success relative to Humira/adalimumab and how prior biologic exposure might affect results; management said adalimumab is the main bar, but they will assess the full data package, and noted patients with prior biologic failure are stratified in the study. They also said they are not ready to quantify the capital needed for a Phase 3 uveitis study until data are in hand.